



- (51) **International Patent Classification:**
C07K 16/28 (2006.01) A61P 37/06 (2006.01)
- (21) **International Application Number:**
PCT/US2021/056289
- (22) **International Filing Date:**
22 October 2021 (22.10.2021)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
63/105,067 23 October 2020 (23.10.2020) US
63/192,984 25 May 2021 (25.05.2021) US
- (71) **Applicant:** ANAPTYSBIO, INC. [US/US]; 10770 Wateridge Circle, Suite 210, San Diego, California 92121 (US).
- (72) **Inventors:** DAHL, Martin Edward; 3980 Via Holgura, San Diego, California 92130 (US). PARMLEY, Stephen; 16172 Selva Drive, San Diego, California 92128 (US). KEHRY, Marilyn; 10440 Rock Creek Drive, San Diego, California 92131 (US). CORREIA, Jean da Silva; 4163 Cleveland Avenue, San Diego, California 92103 (US).
- (74) **Agent:** GASE, John L.; Two Prudential Plaza, 180 N. Stetson Ave., Suite 4900, Chicago, Illinois 60601 (US).
- (81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.
- (84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,


(54) **Title:** B AND T LYMPHOCYTE ATTENUATOR (BTLA) MODULATORS AND METHOD OF USING SAME

FIG. 1

(57) **Abstract:** A BTLA-binding agent and immunoglobulin heavy chain and light chain polypeptides of the binding agent, as well as methods of using the BTLA-binding agent to treat a disorder or disease that is responsive to BTLA agonism, such as an autoimmune or inflammatory disease.

[Continued on next page]

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*

(88) Date of publication of the international search report:

25 August 2022 (25.08.2022)